Homburger advised ADC Therapeutics, a commercial-stage biotechnology company producing antibody drug conjugates (ADCs) for cancer patients, on its 13.4 m of common shares, and, to certain investors who so choose in lieu of common shares, pre-funded
Homburger advised ADC Therapeutics, a commercial-stage biotechnology company producing antibody drug conjugates (ADCs) for cancer patients, on its 13.4 m of common shares, and, to certain investors who so choose in lieu of common shares, pre-funded